每经AI快讯,4月1日,康龙化成(300759.SZ)发布投资者关系活动记录表公告,公司位于北京第二园区的制剂商业化生产车间建设完成,并于2026年第一季度与一家国际大型制药公司签订战略合作协议,为其首个注册申报的口服小分子GLP-1受体激动剂提供商业化生产服务。报告期内,公司新签订单金额同比增长超过14%,新增客户超过950家,活跃客户超过3,300家。来自全球前20大制药企业客户的收入同比实现...
Source Link每经AI快讯,4月1日,康龙化成(300759.SZ)发布投资者关系活动记录表公告,公司位于北京第二园区的制剂商业化生产车间建设完成,并于2026年第一季度与一家国际大型制药公司签订战略合作协议,为其首个注册申报的口服小分子GLP-1受体激动剂提供商业化生产服务。报告期内,公司新签订单金额同比增长超过14%,新增客户超过950家,活跃客户超过3,300家。来自全球前20大制药企业客户的收入同比实现...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.